Formulation and Evaluation of Nanosuspension of Albendazole for Dissolution Enhancement

被引:6
作者
El-Badry, Mahmoud [1 ,2 ]
Fetih, Gihan [2 ]
Salem-Bekhit, Mounir M. [1 ]
Shakeel, Faiyaz [1 ]
机构
[1] King Saud Univ, Dept Pharmaceut, Coll Pharm, Riyadh 11451, Saudi Arabia
[2] Assiut Univ, Dept Pharmaceut, Coll Pharm, Assiut 71526, Egypt
关键词
Albendazole; Nanosuspensions; Hydrophilic Stabilizers; Particle Size; Dissolution Rate; ORAL BIOAVAILABILITY; DRUG-DELIVERY; RELEASE;
D O I
10.1166/nnl.2013.1645
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Poor solubililty of drugs is the major obstacle associated with formulation development. Application of nanotechnology in the formulation development of poorly soluble drugs as nanosuspensions offers the opportunity to address many of the deficiencies associated with these compounds. Therefore, the aim of present study was to develop and evaluate nanosuspensions of albendazole in order to enhance its dissolution, which in turn will ehnace its oral bioavailability. Different nanosuspensions of albendazole were prepared using high pressure homogenization and ultrasonic homogenization techniques. The preliminary study showed that smaller particle sizes of drug were obtained by increasing stirring rate, stirring time, ultrasound intensity and number of cycles. Three different stabilizers (poloxamer 188, polyvinyl alcohol [PVA] and polyvinyl pyrrolidone [PVP]) were investigated either alone or in combination to produce nanoususpensions. Prepared nanoparticles were characterized physically using scanning electron microscopy (SEM), differential scanning calorimetry (DSC) and X-ray diffraction. Prepared formulations were also subjected to in vitro dissolution studies in 0.1 N HCl. The results revealed that poloxamer 188 produces nanoparticles with significantly larger particle size than PVA and PVP. However, combination of PVA and PVP produces nanoparticles with significantly smaller size than other formulations. DSC and X-ray diffraction showed that the crystallinity of the drug was decreased. The dissolution rate of the drug in 0.1 N HCl was significantly higher due to the reduction of the particle size of different formulations and the presence of the hydrophilic stabilizers.
引用
收藏
页码:1024 / 1029
页数:6
相关论文
共 31 条
[1]  
Alanazi F.K., 2007, SCI PHARM, V75, P63
[2]  
[Anonymous], INT CURR PHARM J
[3]   INCREASED SYSTEMIC BIOAVAILABILITY OF ALBENDAZOL WHEN ADMINISTERED WITH SURFACTANTS IN RATS [J].
DELESTAL, JL ;
ALVAREZ, AI ;
VILLAVERDE, C ;
JUSTEL, A ;
PRIETO, JG .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1994, 102 (1-3) :257-260
[4]   Oral bioavailability in sheep of albendazole from a suspension and from a solution containing hydroxypropyl-β-cyclodextrin [J].
Evrard, B ;
Chiap, P ;
DeTullio, P ;
Ghalmi, F ;
Piel, G ;
Van Hees, T ;
Crommen, J ;
Losson, B ;
Delattre, L .
JOURNAL OF CONTROLLED RELEASE, 2002, 85 (1-3) :45-50
[5]   Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions [J].
Gao, Lei ;
Zhang, Dianrui ;
Chen, Minghui ;
Duan, Cunxian ;
Dai, Wenting ;
Jia, Lejiao ;
Zhao, Wenfa .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 355 (1-2) :321-327
[6]  
Jackson C., 2011, INT J PHARM BIOMED R, V2, P59
[7]   Absorption studies of albendazole and some physicochemical properties of the drug and its metabolite albendazole sulphoxide [J].
Jung, H ;
Medina, L ;
Garcia, L ;
Fuentes, I ;
Moreno-Esparza, R .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1998, 50 (01) :43-48
[8]  
Kata M, 1991, Acta Pharm Hung, V61, P23
[9]  
Khokra S., 2012, Int J Pharm Pharm Sci, V4, P461
[10]  
Kohri N., 1991, J PHARM PHARMACOL, V51, P159